Xlife Sciences AGFRA:XLS 57 Buyback Yield % is -2.63 as of Jul. 01, 2026. GuruFocus rates FRA:XLS with a GF Score™ of 57/100 and a GF Value™ of €7.68 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 745 Biotechnology companies, Xlife Sciences AG ranks better than 67.25% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Xlife Sciences AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:XLS vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (FRA:XLS) has a Buyback Yield % of -2.63 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #244 out of 745 companies in the Biotechnology industry, placing it in the top 32.8%.
Is Xlife Sciences AG's Buyback Yield % too high?
Xlife Sciences AG's current Buyback Yield % is -2.63. Based on the distribution chart, Xlife Sciences AG ranks #244 out of 745 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #244 out of 745 companies for Buyback Yield %. This puts Xlife Sciences AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Buyback Yield % is -2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.68, compared to a current price of €20.60 — trading 168.2% above its estimated fair value. The current Buyback Yield % is -2.63. Xlife Sciences AG's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current Buyback Yield % is -2.63 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of €20.60 is trading 168.2% above its estimated GF Value™ of €7.68.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for FRA:XLS:
Buyback Yield %: -2.63
GF Value™: €7.68 vs. price of €20.60 (168.2% above fair value)
No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
57GF Score
Get the complete analysis for FRA:XLS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XLS has been successfully added to your 
